Levonortis

Levonorgestrel, the active ingredient in Levonortis, is a synthetic progestin presented as an intrauterine system for intrauterine use. It is indicated for long‑term contraception and for the management of heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Levonortis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other global markets. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release. The company provides regulatory support and documentation for importers.

Levonorgestrel, delivered via the Levonortis intrauterine system, acts on the hormonal regulation of the menstrual cycle to provide contraceptive and therapeutic effects.

- Long‑term contraception: provides continuous prevention of pregnancy for several years. - Management of heavy menstrual bleeding: reduces menstrual blood loss and improves anemia. - Endometrial hyperplasia: induces regression of hyperplastic endometrial tissue.

Levonortis may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting. - Amenorrhea (absence of periods). - Pelvic or abdominal cramping. - Headache. - Breast tenderness. - Nausea.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Pelvic inflammatory disease. - Ectopic pregnancy if contraception fails. - Severe allergic reaction (anaphylaxis). - Device expulsion. - Hormone‑related mood changes.

Before prescribing Levonortis, clinicians should consider several safety measures.

- Screen for contraindications: assess for active pelvic infection, pregnancy, or known hypersensitivity. - Monitor bleeding patterns: counsel patients on expected changes and when to seek care. - Assess uterine anatomy: ensure appropriate uterine size and shape before insertion. - Educate on device expulsion: advise patients to report missing strings or unusual discharge. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonortis can interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampin and rifabutin: decrease hormone levels, compromising contraceptive effect. - Certain protease inhibitors (e.g., ritonavir): may alter levonorgestrel metabolism.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): may increase levonorgestrel concentrations. - St. John’s wort: may modestly reduce effectiveness. - Some antibiotics (e.g., tetracycline): generally no significant effect but monitoring is advised.